A global phase 3 trial enrolled mHSPC with ≥90% PTEN loss by IHC and randomized 1,012 patients to intermittent capivasertib plus abiraterone/prednisone versus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results